Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia-a randomized controlled feeding trial

BACKGROUND: Carbohydrate restriction shows promise for diabetes, but concerns regarding high saturated fat content of low-carbohydrate diets limit widespread adoption. OBJECTIVES: This preplanned ancillary study aimed to determine how diets varying widely in carbohydrate and saturated fat affect car...

Full description

Bibliographic Details
Main Authors: Ebbeling, C.B (Author), Greco, K.F (Author), Johnson, A. (Author), Knapp, A. (Author), Ludwig, D.S (Author), Ma, C. (Author), Mora, S. (Author), Wong, J.M.W (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
Online Access:View Fulltext in Publisher
LEADER 04778nam a2200865Ia 4500
001 10-1093-ajcn-nqab287
008 220420s2022 CNT 000 0 und d
020 |a 19383207 (ISSN) 
245 1 0 |a Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia-a randomized controlled feeding trial 
260 0 |b NLM (Medline)  |c 2022 
300 |a 9 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1093/ajcn/nqab287 
520 3 |a BACKGROUND: Carbohydrate restriction shows promise for diabetes, but concerns regarding high saturated fat content of low-carbohydrate diets limit widespread adoption. OBJECTIVES: This preplanned ancillary study aimed to determine how diets varying widely in carbohydrate and saturated fat affect cardiovascular disease (CVD) risk factors during weight-loss maintenance. METHODS: After 10-14% weight loss on a run-in diet, 164 participants (70% female; BMI = 32.4 ± 4.8 kg/m2) were randomly assigned to 3 weight-loss maintenance diets for 20 wk. The prepared diets contained 20% protein and differed 3-fold in carbohydrate (Carb) and saturated fat as a proportion of energy (Low-Carb: 20% carbohydrate, 21% saturated fat; Moderate-Carb: 40%, 14%; High-Carb: 60%, 7%). Fasting plasma samples were collected prerandomization and at 20 wk. Lipoprotein insulin resistance (LPIR) score was calculated from triglyceride-rich, high-density, and low-density lipoprotein particle (TRL-P, HDL-P, LDL-P) sizes and subfraction concentrations (large/very large TRL-P, large HDL-P, small LDL-P). Other outcomes included lipoprotein(a), triglycerides, HDL cholesterol, LDL cholesterol, adiponectin, and inflammatory markers. Repeated measures ANOVA was used for intention-to-treat analysis. RESULTS: Retention was 90%. Mean change in LPIR (scale 0-100) differed by diet in a dose-dependent fashion: Low-Carb (-5.3; 95% CI: -9.2, -1.5), Moderate-Carb (-0.02; 95% CI: -4.1, 4.1), High-Carb (3.6; 95% CI: -0.6, 7.7), P = 0.009. Low-Carb also favorably affected lipoprotein(a) [-14.7% (95% CI: -19.5, -9.5), -2.1 (95% CI: -8.2, 4.3), and 0.2 (95% CI: -6.0, 6.8), respectively; P = 0.0005], triglycerides, HDL cholesterol, large/very large TRL-P, large HDL-P, and adiponectin. LDL cholesterol, LDL-P, and inflammatory markers did not differ by diet. CONCLUSIONS: A low-carbohydrate diet, high in saturated fat, improved insulin-resistant dyslipoproteinemia and lipoprotein(a), without adverse effect on LDL cholesterol. Carbohydrate restriction might lower CVD risk independently of body weight, a possibility that warrants study in major multicentered trials powered on hard outcomes. The registry is available through ClinicialTrials.gov: https://clinicaltrials.gov/ct2/show/NCT02068885. © The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition. 
650 0 4 |a adolescent 
650 0 4 |a Adolescent 
650 0 4 |a adult 
650 0 4 |a Adult 
650 0 4 |a aged 
650 0 4 |a Aged 
650 0 4 |a blood 
650 0 4 |a body mass 
650 0 4 |a Body Mass Index 
650 0 4 |a body weight loss 
650 0 4 |a cardiovascular disease risk factors 
650 0 4 |a Cholesterol, HDL 
650 0 4 |a Cholesterol, LDL 
650 0 4 |a complication 
650 0 4 |a controlled study 
650 0 4 |a Diet, Carbohydrate-Restricted 
650 0 4 |a Diet, Reducing 
650 0 4 |a dietary trial 
650 0 4 |a dyslipidemia 
650 0 4 |a Dyslipidemias 
650 0 4 |a female 
650 0 4 |a Female 
650 0 4 |a high density lipoprotein cholesterol 
650 0 4 |a human 
650 0 4 |a Humans 
650 0 4 |a insulin 
650 0 4 |a Insulin 
650 0 4 |a insulin resistance 
650 0 4 |a Insulin Resistance 
650 0 4 |a intention to treat analysis 
650 0 4 |a Intention to Treat Analysis 
650 0 4 |a low calorie diet 
650 0 4 |a low carbohydrate diet 
650 0 4 |a low density lipoprotein cholesterol 
650 0 4 |a low-carbohydrate diet 
650 0 4 |a macronutrients 
650 0 4 |a male 
650 0 4 |a Male 
650 0 4 |a middle aged 
650 0 4 |a Middle Aged 
650 0 4 |a obesity 
650 0 4 |a obesity 
650 0 4 |a Obesity 
650 0 4 |a procedures 
650 0 4 |a randomized controlled trial 
650 0 4 |a saturated fat 
650 0 4 |a treatment outcome 
650 0 4 |a Treatment Outcome 
650 0 4 |a triacylglycerol 
650 0 4 |a Triglycerides 
650 0 4 |a Weight Loss 
650 0 4 |a young adult 
650 0 4 |a Young Adult 
700 1 0 |a Ebbeling, C.B.  |e author 
700 1 0 |a Greco, K.F.  |e author 
700 1 0 |a Johnson, A.  |e author 
700 1 0 |a Knapp, A.  |e author 
700 1 0 |a Ludwig, D.S.  |e author 
700 1 0 |a Ma, C.  |e author 
700 1 0 |a Mora, S.  |e author 
700 1 0 |a Wong, J.M.W.  |e author 
773 |t The American journal of clinical nutrition